Purpose: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in
lung adenocarcinoma, and even rare cases of other subtypes with this mutation, such as …

Introduction: Knowledge about the current status of the epidermal growth factor receptor
(EGFR) has resulted in an improvement in the treatment of non-small cell lung cancer. In …

Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare
in small-cell lung cancer (SCLC). Here, we present a case of an EGFR-mutant gefitinib …

We report a case of small cell lung cancer (SCLC) developing after prolonged treatment
(more than 2 years) for primary adenocarcinoma of the lung, and we show that both the …

In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are
concentrated in exons 18–21, especially in adenocarcinoma (Ad), but these mutations have …

Purpose: It has been reported that the mutations of epidermal growth factor receptor (EGFR)
are detected in lung cancers. Studies of EGFR mutations in large numbers of patients' …

Purpose Some studies have shown that epidermal growth factor receptor (EGFR) mutations
can be heterogeneously distributed in individual tumors. In this study, we re-evaluated the …

Epidermal growth factor receptor (EGFR) mutations are a potential predictor of the
effectiveness of EGFR inhibitors for the treatment of lung cancer. Although EGFR mutations …

Recently it has been reported that mutations in the tyrosine kinase domain of the epidermal
growth factor receptor (EGFR) gene occur in a subset of patients with lung cancer showing a …

Epidermal growth factor receptor (EGFR) gene mutations have been reported to be clinically
significant in non-small cell lung cancer (NSCLC). However, because most previous studies …